| Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More | Frank Vinluan | 09/04/20 | National |
| Nestlé to Swallow Up Peanut Allergy Drug Maker Aimmune in $2.6B Deal | Frank Vinluan | 08/31/20 | San Francisco |
| Still Stuck on Adhesion Issues, FDA Rejects DBV’s Peanut Allergy Patch | Sarah de Crescenzo | 08/04/20 | National |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing | Brenda Sandburg | 03/24/20 | National |
| Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate | Sarah de Crescenzo | 02/05/20 | San Francisco |
| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Advisory Body Backs Aimmune Peanut Allergy Drug, Next Up: the FDA | Frank Vinluan | 09/13/19 | San Francisco |
| FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb | Frank Vinluan | 09/11/19 | San Francisco |
